. 2008 Oct 27;53(1):95–103. doi: 10.1128/AAC.00752-08

TABLE 6.

Dose selections for phase II studies^a

HIV-1 virus	Projected dose^c	C_min,ss (ng/ml)		Equation of protein-corrected EC₅₀ (ng/ml)^b	p10/EC₅₀ ratio
HIV-1 virus	Projected dose^c	Mean	p10^e	Equation of protein-corrected EC₅₀ (ng/ml)^b	p10/EC₅₀ ratio
Wild type	75 mg QD	171.97	67.88	0.5 × 2 = 1.0	68
	100 mg QD	229.29	90.51		91
	150 mg QD	261.12	103.07		103
K103N/Y181C mutant	150 mg QD	261.12	103.07	2.0 × 2 = 4.0	26
	75 mg BID	392.49	173.68		43 (65)^d
	100 mg BID	523.32	231.57		58
	150 mg BID	595.96	263.71		66

C_min,ss values are projected from simulation and were adjusted downward by 36% for BID dose regimens to account for the overestimation of the C_min,ss in the model. p10, 10^th percentile.

The serum shift factor is twofold. EC₅₀ values are from in vitro data.

Each dose regimen is accompanied by 100 mg RTV QD (QD regimens) or 100 mg BID RTV (BID regimens).

The value in parentheses is the 25th percentile for 75 mg BID.

p10, 10th percentile of the projected plasma concentration.